Discover MabDesign
MabDesign, the French association of the industrial sector of biomedicines, aims to support, structure, federate and increase the visibility of the industrial sector of biological medicines.

Access our network
Join the MabDesign network to take advantage of all the advantages and opportunities offered.

Develop your skills
Consult and register for our next training courses in order to acquire new expertise.

Explore our business services
The field of therapeutic antibodies and immunotherapy is growing rapidly. The French industrial ecosystem is rich in innovative companies with considerable potential. MabDesign’s mission is to support them in their development in France and abroad.

Upcoming events
Add your title here
23
Feb.
23-26 February 2026
Partner Event
10
Mar.
March 10-12 2026
Partner Event
17
Mar.
17 March 2026
Partner Event
17
Mar.
March 17-18, 2026
Partner Event
17
Mar.
March 17-19, 2026
Partner Event
23
Mar.
March 23-25, 2026
Partner Event
Our News

ZOOM ON Video - YUMAB
3 February 2026
YUMAB is an innovative biotech company developing next-generation therapeutic antibodies for clients and partners worldwide.
Their platform includes proprietary library technologies, such as fully human antibody libraries, patient-derived libraries, and immune libraries from different species.
YUMAB integrates all technologies from discovery through engineering and AI-enabled lead optimization, providing developability-approved therapeutic lead candidates.

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
30 January 2026
MaaT Pharma Announces a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation

OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativaas New Key Indications for Lusvertikimab
30 January 2026
OSE Immunotherapeutics today announced the selection of two new clinical indications for lusvertikimab (OSE-127):
chronic pouchitis and hidradenitis suppurativa (HS).

Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA Leveraging AI to Advance Scientific Instrumentation and Accelerate Laboratory Performance
30 January 2026
Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA Leveraging AI to Advance Scientific Instrumentation and Accelerate Laboratory Performance
OUR BOARD OF DIRECTORS





























































































































































































































































































































































































